CELLDEX THERAPEUTICS INC NEW's ticker is CLDX and the CUSIP is 15117B202. A total of 161 filers reported holding CELLDEX THERAPEUTICS INC NEW in Q1 2023. The put-call ratio across all filers is 0.51 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $339,300 | -88.9% | 10,000 | -88.2% | 0.10% | -91.6% |
| Q1 2023 | $3,045,743 | +24.9% | 84,651 | +54.8% | 1.26% | +80.3% |
| Q4 2022 | $2,437,934 | +62.7% | 54,699 | +2.7% | 0.70% | +37.5% |
| Q3 2022 | $1,498,000 | -23.2% | 53,275 | -26.3% | 0.51% | -15.5% |
| Q2 2022 | $1,950,000 | +661.7% | 72,322 | +58.8% | 0.60% | +466.0% |
| Q1 2022 | $256,000 | -85.3% | 45,538 | +0.9% | 0.11% | -85.0% |
| Q4 2021 | $1,744,000 | -15.5% | 45,132 | +18.0% | 0.71% | -39.4% |
| Q3 2021 | $2,065,000 | -29.4% | 38,243 | +285.5% | 1.17% | -10.6% |
| Q2 2021 | $2,926,000 | +108.0% | 9,921 | -87.6% | 1.30% | +59.7% |
| Q4 2020 | $1,407,000 | – | 80,282 | – | 0.82% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Kynam Capital Management, LP | 3,200,000 | $88,064,000 | 14.40% |
| Octagon Capital Advisors LP | 759,898 | $20,912,393 | 3.21% |
| TSP Capital Management Group, LLC | 251,695 | $6,926,645 | 2.67% |
| 5AM Venture Management, LLC | 310,270 | $8,538,630 | 2.46% |
| COMMODORE CAPITAL LP | 706,665 | $19,447,421 | 2.27% |
| ACUTA CAPITAL PARTNERS, LLC | 122,341 | $3,366,824 | 2.26% |
| Redmile Group, LLC | 1,635,938 | $45,021,014 | 2.14% |
| RTW INVESTMENTS, LP | 3,463,201 | $95,307,292 | 2.01% |
| Eversept Partners, LP | 588,143 | $16,185,695 | 1.37% |
| Affinity Asset Advisors, LLC | 150,000 | $4,128,000 | 1.16% |